Cardiovascular Drugs Practice Questions

Q: What is the major clinical use of nimodipine?

Subarachnoid haemorrhage. **Explanation:** **Nimodipine** is a second-generation dihydropyridine calcium channel blocker (CCB). While it shares the basic mechanism of other CCBs (blocking L-type calcium channels), it possesses unique pharmacological properties that dictate its clinical use. **1. Why Subarachnoid Haemorrhage (SAH) is correct:** Nimodipine is highly **lipophilic**, allowing it to readily cross the blood-brain barrier. It has a high affinity for cerebral blood vessels. Following a subarachnoid haemorrhage, patients often suffer from delayed **cerebral vasospasm**, which can lead to secondary ischemic neurological deficits. Nimodipine is the drug of choice to prevent and treat this vasospasm, thereby improving neurological outcomes. **2. Why other options are incorrect:** * **Raynaud’s Phenomenon:** While CCBs like Nifedipine or Amlodipine are used to treat Raynaud’s, Nimodipine is not the preferred agent due to its cerebrovascular specificity. * **Hypertension & Angina:** Although Nimodipine can cause vasodilation, it is significantly less potent than Amlodipine or Nifedipine for systemic hypertension or stable angina. Its short half-life and specific action on cerebral vessels make it unsuitable for routine systemic cardiovascular management. **3. High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** In SAH, Nimodipine is typically given **orally** (or via nasogastric tube). **Caution:** It should never be injected intravenously from a capsule intended for oral use, as this can cause fatal hypotension. * **Mnemonic:** Remember **"Nimo"** for **"Neuro"** (Cerebral specific). * **Other CCB Specifics:** * **Nicardipine:** Often used for hypertensive emergencies. * **Clevidipine:** Ultra-short-acting IV CCB used for acute BP control.

Q: Which of the following drugs used in the management of pulmonary hypertension acts by inhibiting the phosphodiesterase enzyme?

Sildenafil. **Explanation:** **Sildenafil** is the correct answer because it is a potent and selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the pulmonary vasculature, PDE-5 is responsible for the degradation of cyclic Guanosine Monophosphate (cGMP). By inhibiting this enzyme, Sildenafil increases intracellular cGMP levels, which leads to nitric oxide-mediated smooth muscle relaxation and potent vasodilation of the pulmonary arteries, thereby reducing pulmonary artery pressure. **Analysis of Incorrect Options:** * **A. Epoprostenol:** This is a synthetic **Prostacyclin (PGI2) analogue**. It acts by binding to IP receptors to increase cAMP, causing direct vasodilation and inhibition of platelet aggregation. * **B. Bosentan:** This is a dual **Endothelin Receptor Antagonist (ERA)**. It blocks both $ET_A$ and $ET_B$ receptors, preventing the potent vasoconstrictive effects of endothelin-1. * **C. Nifedipine:** This is a **Calcium Channel Blocker (CCB)**. It is used only in a small subset of pulmonary hypertension patients who show a positive "vasoreactivity test" during right heart catheterization. **NEET-PG High-Yield Pearls:** * **Tadalafil** is another PDE-5 inhibitor used in PAH; it has a longer half-life than Sildenafil. * **Riociguat** is a "Soluble Guanylate Cyclase (sGC) Stimulator" often confused with PDE-5 inhibitors; it increases cGMP production directly rather than preventing its breakdown. * **Drug of Choice (DOC):** While treatment is individualized, PDE-5 inhibitors are often first-line oral agents for WHO Group 1 PAH. * **Contraindication:** Never co-administer PDE-5 inhibitors with **Nitrates**, as this can lead to life-threatening hypotension due to synergistic increases in cGMP.

Q: Statins act on which enzyme?

HMG CoA reductase. **Explanation:** **Correct Answer: D. HMG CoA reductase** Statins (HMG-CoA reductase inhibitors) are the first-line drugs for treating hypercholesterolemia. They act by competitively inhibiting the enzyme **3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase**. This enzyme is the **rate-limiting step** in the mevalonate pathway of endogenous cholesterol synthesis. By inhibiting this enzyme, statins decrease intracellular cholesterol levels, which triggers an up-regulation of LDL receptors on hepatocytes, leading to increased clearance of LDL-C from the blood. **Analysis of Incorrect Options:** * **A & B (Acyl CoA synthetase/reductase):** These enzymes are involved in fatty acid metabolism and the activation of long-chain fatty acids, not the primary rate-limiting step of cholesterol synthesis. * **C (HMG CoA synthetase):** This enzyme catalyzes the formation of HMG-CoA from Acetyl-CoA and Acetoacetyl-CoA. While it is part of the pathway, it is not the rate-limiting step and is not the target of statin therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Pleiotropic Effects:** Statins have benefits beyond lipid-lowering, including plaque stabilization, anti-inflammatory effects, and improved endothelial function. * **Timing of Dose:** Since cholesterol synthesis peaks at night, statins with short half-lives (e.g., Lovastatin, Simvastatin) should be taken at **bedtime**. Long-acting statins (Atorvastatin, Rosuvastatin) can be taken any time. * **Adverse Effects:** The most important side effects are **myopathy/rhabdomyolysis** (monitored via CPK levels) and hepatotoxicity (monitored via LFTs). * **Contraindication:** Statins are strictly **contraindicated in pregnancy** (Teratogenic).

Q: Digoxin toxicity may result from the concurrent administration of digoxin with all of the following drugs EXCEPT?

Triamterene. ### Explanation The core concept behind this question is the relationship between **serum potassium levels** and **digoxin toxicity**. Digoxin competes with potassium for binding sites on the Na+/K+-ATPase pump. Therefore, **hypokalemia** (low potassium) increases digoxin binding, leading to toxicity. **1. Why Triamterene is the Correct Answer:** Triamterene is a **potassium-sparing diuretic**. It inhibits sodium reabsorption in the distal tubule and collecting duct without causing potassium loss. By maintaining or slightly increasing serum potassium levels, it prevents the increased binding of digoxin to the ATPase pump, thereby **reducing** the risk of toxicity rather than causing it. **2. Why the Other Options are Incorrect:** * **Quinidine (Option A):** This is a classic drug interaction. Quinidine reduces the renal and extra-renal clearance of digoxin and displaces it from tissue binding sites, significantly increasing plasma digoxin levels. * **Furosemide (Option D) & Hydrochlorothiazide (Option B):** These are loop and thiazide diuretics, respectively. Both are **potassium-wasting diuretics**. They cause hypokalemia, which sensitizes the myocardium to digoxin, precipitating toxicity even if digoxin levels are within the "normal" therapeutic range. **3. Clinical Pearls for NEET-PG:** * **Electrolyte Triad of Digoxin Toxicity:** Hypokalemia, Hypomagnesemia, and Hypercalcemia all predispose a patient to toxicity. * **Most Common Arrhythmia:** Atrial tachycardia with AV block. * **Most Specific Arrhythmia:** Bidirectional Ventricular Tachycardia. * **Management:** Digibind (Digoxin-specific Fab fragments) is the antidote of choice for severe toxicity. * **Other drugs increasing Digoxin levels:** Verapamil, Amiodarone, and Erythromycin.

Q: Which of the following does not result in the release of nitric oxide?

Fenoldopam. ### Explanation **Correct Option: A. Fenoldopam** **Mechanism of Action:** Fenoldopam is a selective **Dopamine-1 (D1) receptor agonist**. It causes vasodilation by stimulating D1 receptors, which increases intracellular **cAMP** (cyclic Adenosine Monophosphate) levels, leading to the relaxation of vascular smooth muscle. Unlike the other drugs listed, its mechanism is entirely independent of the Nitric Oxide (NO)-cGMP pathway. It is primarily used in the management of hypertensive emergencies, especially when renal perfusion needs to be maintained. **Analysis of Incorrect Options:** * **B. Hydralazine:** This is a direct-acting vasodilator. While its exact mechanism is complex, it is known to stimulate the release of **Nitric Oxide** from the vascular endothelium, leading to cGMP-mediated vasodilation of arterioles [1]. * **C. Nitroprusside:** This is a parenteral vasodilator that acts as an **NO donor** [2]. It is non-enzymatically converted to Nitric Oxide in the blood, which activates guanylyl cyclase to increase cGMP, dilating both arterioles and venules. * **D. Nitroglycerin:** This organic nitrate undergoes **enzymatic bioactivation** (via mitochondrial aldehyde dehydrogenase) to release Nitric Oxide, primarily causing venodilation and reducing cardiac preload [2, 3]. **High-Yield Clinical Pearls for NEET-PG:** * **Fenoldopam Unique Property:** It is the only intravenous antihypertensive that improves **renal perfusion** (natriuresis and diuresis) while lowering blood pressure, making it ideal for hypertensive emergencies with renal compromise. * **Nitroprusside Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Nitrate Tolerance:** Continuous use of Nitroglycerin leads to "tachyphylaxis" due to the depletion of free sulfhydryl groups; a "nitrate-free interval" (8–12 hours) is required to restore sensitivity.

Q: Which is the best inotropic drug for use in right heart failure?

Milrinone. **Explanation:** **Milrinone** is a Phosphodiesterase-3 (PDE3) inhibitor. It increases intracellular cAMP in the myocardium, leading to increased contractility (inotropy). Crucially, it also increases cAMP in vascular smooth muscle, causing systemic and **pulmonary vasodilation** (lusitropy and vasodilation). In right heart failure (RHF), the right ventricle (RV) is often struggling against high pulmonary vascular resistance (PVR). Milrinone is the "best" choice because it provides "Inodilatation"—improving RV contractility while simultaneously decreasing the afterload on the RV by dilating the pulmonary artery. **Analysis of Incorrect Options:** * **Dobutamine:** A $\beta_1$ agonist that increases cardiac output. While it is a potent inotrope, it has less pronounced effects on reducing pulmonary vascular resistance compared to Milrinone and can increase myocardial oxygen demand significantly. * **Digoxin:** A weak inotrope that inhibits Na+/K+ ATPase. It is primarily used for rate control in atrial fibrillation or symptomatic relief in chronic HFrEF, but it is not the drug of choice for acute right heart failure management. * **Dopamine:** At higher doses, it has $\alpha_1$ agonistic effects which can increase systemic and pulmonary vascular resistance, potentially worsening the strain on a failing right ventricle. **High-Yield Clinical Pearls for NEET-PG:** * **"Inodilators":** Milrinone and Levosimendan are categorized as inodilators (Inotrope + Vasodilator). * **Renal Caution:** Milrinone is renally cleared; dosage adjustment is required in renal failure. * **Side Effect:** The most common side effect of Milrinone is hypotension (due to vasodilation) and arrhythmias. * **Mechanism:** PDE3 inhibition $\rightarrow$ $\uparrow$ cAMP $\rightarrow$ $\uparrow$ Calcium influx in heart (contraction) and $\uparrow$ Calcium uptake in smooth muscle (relaxation).

Q: Which of the following is a K+ channel opener?

Minoxidil. **Explanation:** **Mechanism of Action (The Correct Answer):** **Minoxidil** is a potent direct-acting vasodilator that acts as a **Potassium (K+) channel opener**. It works by opening ATP-sensitive K+ channels in the smooth muscle cells of peripheral arterioles. This leads to K+ efflux, causing membrane hyperpolarization, which prevents the opening of voltage-gated calcium channels. The resulting decrease in intracellular calcium leads to smooth muscle relaxation and profound vasodilation. **Analysis of Incorrect Options:** * **A. Nifedipine:** This is a **Dihydropyridine Calcium Channel Blocker (CCB)**. It lowers blood pressure by inhibiting L-type calcium channels in vascular smooth muscle, not by acting on K+ channels. * **C. Enalapril:** This is an **ACE Inhibitor**. It works by inhibiting the Angiotensin-Converting Enzyme, thereby reducing the production of Angiotensin II (a potent vasoconstrictor) and decreasing aldosterone levels. * **D. Atenolol:** This is a **Cardioselective $\beta_1$-blocker**. It reduces blood pressure primarily by decreasing cardiac output and inhibiting renin release from the juxtaglomerular apparatus. **High-Yield Clinical Pearls for NEET-PG:** * **Other K+ Channel Openers:** Nicorandil (used in angina), Diazoxide (used in insulinoma/hypertensive emergencies), and Pinacidil. * **Side Effects of Minoxidil:** It causes significant salt and water retention (often requiring diuretics) and reflex tachycardia (requiring $\beta$-blockers). * **Hypertrichosis:** A unique side effect of Minoxidil is excessive hair growth; hence, it is used topically for treating **Androgenetic Alopecia**. * **Diazoxide** is unique because it also inhibits insulin release, making it useful in treating hypoglycemia due to hyperinsulinism.

Q: What are the most potent drugs for reducing plasma cholesterol levels?

Statins. **Statins (HMG-CoA Reductase Inhibitors)** are the most potent drugs for lowering LDL-cholesterol [2]. They work by competitively inhibiting the rate-limiting enzyme in cholesterol synthesis, HMG-CoA reductase [1, 2]. This reduction in intracellular cholesterol triggers a compensatory **upregulation of LDL receptors** on hepatocytes, leading to increased clearance of LDL from the plasma. Statins can reduce LDL levels by 20% to over 60%, depending on the dose and potency (e.g., Atorvastatin, Rosuvastatin) [2]. **Why other options are incorrect:** * **Plant sterols:** These compete with cholesterol for micellar solubilization in the intestine. While they reduce absorption, their efficacy is modest (approx. 10% reduction) compared to statins. * **Fibrates (e.g., Fenofibrate):** These are agonists of **PPAR-α**. Their primary role is reducing **triglycerides** and increasing HDL; they have a variable and much weaker effect on LDL-C. * **Anion exchange resins (e.g., Cholestyramine):** These sequester bile acids in the gut. While effective, they are less potent than statins and often cause GI side effects, limiting their clinical utility as first-line monotherapy. **High-Yield NEET-PG Pearls:** * **Pleiotropic effects:** Statins provide cardiovascular benefits beyond lipid lowering, such as plaque stabilization and anti-inflammatory effects [2]. * **Side effects:** Monitor for **myopathy/rhabdomyolysis** (increased risk when combined with fibrates) and hepatotoxicity [2]. * **Timing:** Most statins are given at bedtime because hepatic cholesterol synthesis peaks at night (except Atorvastatin and Rosuvastatin, which have long half-lives). * **Newer agents:** PCSK9 inhibitors (e.g., Evolocumab) are now considered more potent than statins but were not listed in the options.

Q: Which of the following drugs is commonly associated with causing a cough?

Lisinopril. **Explanation:** **Lisinopril** is an **ACE (Angiotensin-Converting Enzyme) inhibitor**. The dry, hacking cough associated with this class of drugs occurs in approximately 5–20% of patients. * **Mechanism:** ACE is identical to Kininase II, the enzyme responsible for the degradation of **bradykinin** and **Substance P**. When ACE is inhibited, these inflammatory autacoids accumulate in the upper respiratory tract and lungs. Bradykinin sensitizes sensory nerve endings, leading to the characteristic dry cough. **Analysis of Incorrect Options:** * **B. Propranolol:** A non-selective beta-blocker. While it can cause **bronchospasm** (especially in asthmatics) by blocking $\beta_2$ receptors, it does not typically cause a dry cough. * **C. Verapamil:** A non-dihydropyridine Calcium Channel Blocker (CCB). Its most characteristic side effect is **constipation** and peripheral edema, not cough. * **D. Sodium nitroprusside:** A potent vasodilator used in hypertensive emergencies. Its major toxicity is related to **cyanide and thiocyanate accumulation**, leading to metabolic acidosis and psychosis. **NEET-PG High-Yield Pearls:** 1. **Management:** If a patient develops an ACEI-induced cough, the drug should be discontinued and switched to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not affect bradykinin levels. 2. **Gender Predilection:** The cough is more common in **females** and patients of Chinese descent. 3. **Other ACEI Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria/Potassium excess, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased renin, Leukopenia).

Q: A patient on antihypertensive medication develops a dry cough. Which of the following drugs might be responsible for this condition?

ACE inhibitors. **Explanation:** **Correct Option: B. ACE inhibitors** ACE inhibitors (e.g., Enalapril, Lisinopril) are the most common cause of drug-induced dry cough, occurring in 5–20% of patients. The underlying mechanism involves the inhibition of **Angiotensin-Converting Enzyme (ACE)**, which is also responsible for the degradation of **Bradykinin** and **Substance P**. When ACE is inhibited, these inflammatory peptides accumulate in the upper respiratory tract and lungs, sensitizing sensory nerve endings and triggering a persistent, non-productive cough. **Incorrect Options:** * **A. Diuretics:** Common side effects include electrolyte imbalances (hypokalemia) and hyperuricemia, but they do not affect the kinin system or cause a cough. * **C. Calcium Channel Blockers (CCBs):** These typically cause peripheral edema (Amlodipine), headache, or constipation (Verapamil), but not respiratory symptoms. * **D. Beta-blockers:** While non-selective beta-blockers (e.g., Propranolol) can cause **bronchospasm** or wheezing in asthmatics due to $\beta_2$ blockade, they do not cause a dry cough in the general hypertensive population. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** If a patient develops an ACEI-induced cough, the drug should be stopped. The cough usually resolves within 1–4 weeks. * **Alternative:** **Angiotensin Receptor Blockers (ARBs)** like Losartan are the preferred alternative because they do not affect ACE or bradykinin levels. * **Other Side Effects of ACEIs:** Remember the mnemonic **CAPTOPRIL**: **C**ough, **A**ngioedema, **P**roteinuria, **T**aste changes, **O**rthostatic hypotension, **P**regnancy contraindication (Teratogenic), **R**enal artery stenosis contraindication, **I**ncreased potassium (Hyperkalemia), **L**eukopenia.

Question 1

What is the major clinical use of nimodipine?

Accepted Answer

Subarachnoid haemorrhage

Answer

Raynaud's phenomenon

Answer

Hypertension

Answer

Angina

Question 2

Which of the following drugs used in the management of pulmonary hypertension acts by inhibiting the phosphodiesterase enzyme?

Accepted Answer

Sildenafil

Answer

Epoprostenol

Answer

Bosentan

Answer

Nifedipine

Question 3

Statins act on which enzyme?

Accepted Answer

HMG CoA reductase

Answer

Acyl CoA synthetase

Answer

Acyl CoA reductase

Answer

HMG CoA synthetase

Question 4

Digoxin toxicity may result from the concurrent administration of digoxin with all of the following drugs EXCEPT?

Accepted Answer

Triamterene

Answer

Quinidine

Answer

Hydrochlorothiazide

Answer

Furosemide

Question 5

Which of the following does not result in the release of nitric oxide?

Accepted Answer

Fenoldopam

Answer

Hydralazine

Answer

Nitroprusside

Answer

Nitroglycerin

Question 6

Which is the best inotropic drug for use in right heart failure?

Accepted Answer

Milrinone

Answer

Dobutamine

Answer

Digoxin

Answer

Dopamine

Question 7

Which of the following is a K+ channel opener?

Accepted Answer

Minoxidil

Answer

Nifedipine

Answer

Enalapril

Answer

Atenolol

Question 8

What are the most potent drugs for reducing plasma cholesterol levels?

Accepted Answer

Statins

Answer

Plant sterols

Answer

Fibrates

Answer

Anion exchange resins

Question 9

Which of the following drugs is commonly associated with causing a cough?

Accepted Answer

Lisinopril

Answer

Propranolol

Answer

Verapamil

Answer

Sodium nitroprusside

Question 10

A patient on antihypertensive medication develops a dry cough. Which of the following drugs might be responsible for this condition?

Accepted Answer

ACE inhibitors

Answer

Diuretics

Answer

Calcium channel blockers

Answer

Beta blockers

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?